Steve Scaglione1, William Adams2, Allyce Caines3, Pauline Devlin4, Sahil Mittal5, Amit G Singal6,7, Neehar D Parikh4. 1. Department of Internal Medicine, Loyola University Medical Center, 2160 S, 1st Avenue, Maywood, IL, 60153, USA. sscagli@lumc.edu. 2. Department of Public Health Sciences, Loyola University Medical Center, Maywood, IL, USA. 3. Department of Internal Medicine, Loyola University Medical Center, 2160 S, 1st Avenue, Maywood, IL, 60153, USA. 4. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 5. Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA. 6. Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health and Hospital System, Dallas, TX, USA. 7. Harold C. Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Abstract
BACKGROUND: Racial/ethnic disparities in prognosis have been reported in patients with hepatocellular carcinoma (HCC); however, few studies have evaluated racial/ethnic disparities in the context of insurance status. AIMS: Characterize racial/ethnic and insurance status in early tumor detection, receipt of curative therapy and overall survival in a multicenter diverse cohort of HCC patients from the USA. STUDY: We included patients with HCC diagnosed between June 2012 and May 2013 at four centers in the USA. Generalized linear mixed effects models were used to compare early tumor detection (defined using Milan Criteria) and curative treatment receipt (liver transplantation, surgical resection, or local ablation) as a function of patient race/ethnicity and insurance status. A multivariable frailty survival model was used to compare risk of death between patient groups. RESULTS: Of 379 HCC patients (52.8% non-Hispanic White, 19.5% Hispanic White, 19.8% Black), 46.4% and 48.0% were found at an early stage and underwent curative therapy, respectively, and median overall survival of the cohort was 25.7 months. Early detection of HCC was associated with gastroenterology subspecialty care and receipt of HCC surveillance but not race/ethnicity or insurance status in adjusted models. However, commercial insurance was significantly associated with higher odds of curative treatment receipt, which in turn was the strongest correlate for overall survival. After adjusting for health system and insurance status, race/ethnicity was not associated with curative treatment receipt or overall survival. CONCLUSIONS: Insurance status and access to gastroenterology subspecialty care may be important drivers of racial/ethnic disparities in prognosis among HCC patients.
BACKGROUND: Racial/ethnic disparities in prognosis have been reported in patients with hepatocellular carcinoma (HCC); however, few studies have evaluated racial/ethnic disparities in the context of insurance status. AIMS: Characterize racial/ethnic and insurance status in early tumor detection, receipt of curative therapy and overall survival in a multicenter diverse cohort of HCCpatients from the USA. STUDY: We included patients with HCC diagnosed between June 2012 and May 2013 at four centers in the USA. Generalized linear mixed effects models were used to compare early tumor detection (defined using Milan Criteria) and curative treatment receipt (liver transplantation, surgical resection, or local ablation) as a function of patient race/ethnicity and insurance status. A multivariable frailty survival model was used to compare risk of death between patient groups. RESULTS: Of 379 HCCpatients (52.8% non-Hispanic White, 19.5% Hispanic White, 19.8% Black), 46.4% and 48.0% were found at an early stage and underwent curative therapy, respectively, and median overall survival of the cohort was 25.7 months. Early detection of HCC was associated with gastroenterology subspecialty care and receipt of HCC surveillance but not race/ethnicity or insurance status in adjusted models. However, commercial insurance was significantly associated with higher odds of curative treatment receipt, which in turn was the strongest correlate for overall survival. After adjusting for health system and insurance status, race/ethnicity was not associated with curative treatment receipt or overall survival. CONCLUSIONS: Insurance status and access to gastroenterology subspecialty care may be important drivers of racial/ethnic disparities in prognosis among HCCpatients.
Authors: Fatma M Shebl; David E Capo-Ramos; Barry I Graubard; Katherine A McGlynn; Sean F Altekruse Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-05 Impact factor: 4.254
Authors: Amit G Singal; Sahil Mittal; Olutola A Yerokun; Chul Ahn; Jorge A Marrero; Adam C Yopp; Neehar D Parikh; Steve J Scaglione Journal: Am J Med Date: 2017-02-14 Impact factor: 4.965
Authors: Victor Zaydfudim; Martin A Whiteside; Marie R Griffin; Irene D Feurer; J Kelly Wright; C Wright Pinson Journal: Ann Surg Oncol Date: 2010-06-29 Impact factor: 5.344
Authors: Abby B Siegel; Russell B McBride; Hashem B El-Serag; Dawn L Hershman; Robert S Brown; John F Renz; Jean Emond; Alfred I Neugut Journal: Am J Gastroenterol Date: 2007-11-15 Impact factor: 10.864
Authors: Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein Journal: Nature Date: 2009-08-16 Impact factor: 49.962
Authors: Katherine Baicker; Sarah L Taubman; Heidi L Allen; Mira Bernstein; Jonathan H Gruber; Joseph P Newhouse; Eric C Schneider; Bill J Wright; Alan M Zaslavsky; Amy N Finkelstein Journal: N Engl J Med Date: 2013-05-02 Impact factor: 91.245
Authors: Nicole E Rich; Christian Carr; Adam C Yopp; Jorge A Marrero; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2020-12-30 Impact factor: 11.382
Authors: Aman Opneja; Gino Cioffi; Asrar Alahmadi; Nelroy Jones; Tin-Yun Tang; Nirav Patil; David L Bajor; Joel N Saltzman; Amr Mohamed; Eva Selfridge; Ankit Mangla; Jill Barnholtz-Sloan; Richard T Lee Journal: Cancer Med Date: 2021-05-31 Impact factor: 4.711